犬異位性皮膚炎市場規模、佔有率和成長分析：按治療方法、給藥途徑、分銷管道、疾病嚴重程度、最終用戶和地區分類－2026-2033年產業預測

2024 年全球犬類異位性皮膚炎市場價值為 29 億美元，預計到 2025 年將成長至 31.3 億美元，到 2033 年將成長至 58 億美元，預測期（2026-2033 年）複合年成長率為 8.0%。

全球犬類異位性皮膚炎市場正經歷強勁成長，其促進因素包括寵物「人性化」趨勢的日益增強以及犬類過敏性皮膚病發病率的上升。寵物飼主越來越關注寵物的健康，因此在伴侶動物醫療保健方面的支出不斷增加，對長期治療方法的需求也日益成長。皮膚病治療技術的進步和獸醫診斷技術的改進，為創新標靶治療（例如單株抗體和先進的局部用藥製劑）的研發鋪平了道路。然而，高昂的治療費用、某些地區認知度較低以及用藥依從性問題等挑戰可能會阻礙市場滲透。發展中地區寵物飼養量的增加以及獸醫和製藥業之間合作的加強，為市場成長提供了巨大的機會。

全球犬異位性皮膚炎市場按治療方法、給藥途徑、分銷管道、疾病嚴重程度、最終用戶和地區進行細分。依治療方法分類，市場分為皮質類固醇、Cyclosporine、單株抗體、抗組織胺、免疫療法和其他療法。依給藥途徑分類，市場分為口服、注射及外用藥物。依銷售管道分類，市場分為獸醫院和診所、零售藥局和線上藥局。依疾病嚴重程度分類，市場分為輕度、中度和重度。依最終用戶分類，市場分為獸醫院和診所、寵物飼主和獸醫診所。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球犬異位性皮膚炎市場成長要素

由於寵物飼主數量的增加以及人們對家庭寵物護理觀念的轉變，全球犬類異位性皮膚炎市場正經歷顯著成長。隨著人們對特應性疾病的認知不斷提高，寵物飼主將愛犬視為家庭成員，並更積極地尋求獸醫護理。這一趨勢鼓勵人們諮詢獸醫專業人士並遵循其建議，從而進一步推動市場成長。為此，獸醫院正在加強檢測和治療服務，而私人企業則專注於產品創新和資訊廣泛傳播；所有這些因素都促進了市場的整體擴張。

全球犬異位性皮膚炎市場的限制因素

由於人們對犬異位性皮膚炎的症狀及其長期管理的必要性普遍缺乏了解，全球犬異位性皮膚炎市場面臨著許多限制因素。犬飼主獸醫專業人員對現有治療方案的認知不足，會阻礙及時診斷和有效治療。如果寵物飼主認為這種皮膚問題輕微或不如其他慢性疾病嚴重，他們可能會避免就醫，而依賴家庭療法。這種對症治療的傾向進一步降低了進行全面診斷評估和處方治療的動機，最終阻礙了新治療方法的上市。

犬異位性皮膚炎的全球市場趨勢

全球犬異位性皮膚炎市場正經歷著向精準獸醫學的顯著轉變，個人化和標靶治療方案的趨勢尤其突出。基於生物標記的診斷技術的創新，推動了更有效的免疫調節劑和先進外用製劑的研發，以滿足每隻狗的個別需求。專科獸醫與製藥公司的合作正在加速這些標靶治療的開發，而綜合護理模式則強調了整體皮膚健康和生活品質的重要性。這種對個人化治療方案和預防策略的關注正在改變市場格局，形成清晰的臨床差異化，並最終改善患犬的治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球犬異位性皮膚炎市場規模：依治療類型分類

• 皮質類固醇
• Cyclosporine
• 單株抗體
• 抗組織胺藥
• 免疫療法
• 其他

全球犬異位性皮膚炎市場規模：依給藥途徑分類

• 口服
• 注射藥物
• 外用

全球犬類異位性皮膚炎市場規模：依分銷管道分類

• 獸醫醫院和獸醫診所
• 零售藥房
• 網路藥房

全球犬異位性皮膚炎市場規模：依疾病嚴重程度分類

• 溫和的
• 緩和
• 嚴重

全球犬類異位性皮膚炎市場規模：依最終用戶分類

• 動物診所
• 寵物飼主
• 動物醫院

全球犬類異位性皮膚炎市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Zoetis Inc.
• Elanco Animal Health
• Boehringer Ingelheim Animal Health
• Virbac SA
• Ceva Sante Animale
• Dechra Pharmaceuticals
• Vetoquinol SA
• Kindred Biosciences（Elanco）
• Bimeda Inc.
• Norbrook Laboratories
• IDEXX Laboratories（diagnostics overlap）
• Bayer Animal Health（now part of Elanco）
• Merck Animal Health
• PetIQ Inc.
• Toray Industries（biologics involvement）
• Dermcare-Vet Pty Ltd
• Nextmune
• Hester Biosciences Ltd
• Indian Immunologicals Ltd
• Zydus Animal Health

結論與建議

Global Canine Atopic Dermatitis Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.13 Billion in 2025 to USD 5.8 Billion by 2033, growing at a CAGR of 8.0% during the forecast period (2026-2033).

The global canine atopic dermatitis market is experiencing robust growth fueled by several factors, including the rising trend of pet humanization and the increasing incidence of allergic skin disorders in dogs. Pet owners are becoming more conscious of their pets' health, leading to heightened spending on companion animal healthcare and a growing demand for long-term treatment options. Advancements in dermatology therapies and improved veterinary diagnostics are paving the way for innovative targeted therapies, including monoclonal antibodies and advanced topical formulations. However, challenges such as high treatment costs, limited awareness in specific regions, and compliance issues may hinder market penetration. As pet ownership expands in developing regions and veterinary-pharmaceutical collaboration strengthens, substantial opportunities for market growth are anticipated.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Canine Atopic Dermatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Canine Atopic Dermatitis Market Segments Analysis

Global canine atopic dermatitis market is segmented by treatment type, route of administration, distribution channel, disease severity, end-user, and region. Based on treatment type, the market is segmented into corticosteroids, cyclosporine, monoclonal antibodies, antihistamines, immunotherapy, and others. Based on route of administration, the market is segmented into oral, injectable, and topical. Based on distribution channel, the market is segmented into veterinary clinics & hospitals, retail pharmacies, and online pharmacies. Based on disease severity, the market is segmented into mild, moderate, and severe. Based on end-user, the market is segmented into veterinary clinics, pet owners, and veterinary hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Canine Atopic Dermatitis Market

The Global Canine Atopic Dermatitis market is experiencing significant growth due to the increasing number of pet owners and shifting attitudes towards pet care in domestic environments. As awareness regarding atopic conditions rises, pet owners are more proactive in seeking veterinary treatment for their dogs, viewing them as integral family members. This trend encourages consultations with veterinary professionals and adherence to their recommendations, further fueling market growth. In response, veterinary practices are enhancing their testing and management offerings, while private sector companies are driven to innovate new products and disseminate information more widely, thereby supporting the overall expansion of this market.

Restraints in the Global Canine Atopic Dermatitis Market

The Global Canine Atopic Dermatitis market faces significant constraints due to a general lack of awareness about the condition's symptoms and the long-term management necessities associated with it. Limited understanding of available therapeutic options among both dog owners and veterinary professionals can hinder timely diagnosis and effective treatment. If pet owners perceive the skin issue as trivial or not significant compared to other chronic conditions, they may forego veterinary consultations in favor of home remedies. This tendency to adopt a palliative approach further reduces the incentive for comprehensive diagnostic evaluations and prescription treatments, ultimately impeding the adoption of new therapies in the market.

Market Trends of the Global Canine Atopic Dermatitis Market

The Global Canine Atopic Dermatitis market is witnessing a significant trend towards precision veterinary therapies, highlighting the shift towards personalized and targeted treatment solutions. Innovations in biomarker-based diagnostics are enabling more effective immunomodulators and advanced topical formulations that cater to individual canine needs. Collaborative efforts between specialty veterinarians and pharmaceutical companies are enhancing the development of these targeted therapies, while integrative care models emphasize the importance of overall skin health and quality of life. This focus on customized treatment plans and preventive strategies is transforming the market landscape, offering distinct clinical differentiators and improved outcomes for affected dogs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Canine Atopic Dermatitis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Cyclosporine
• Monoclonal Antibodies
• Antihistamines
• Immunotherapy
• Others

Global Canine Atopic Dermatitis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Canine Atopic Dermatitis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics & Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Canine Atopic Dermatitis Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild
• Moderate
• Severe

Global Canine Atopic Dermatitis Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics
• Pet Owners
• Veterinary Hospitals

Global Canine Atopic Dermatitis Market Size & CAGR (2026-2033)

• North America (Treatment Type, Route of Administration, Distribution Channel, Disease Severity, End-User)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Distribution Channel, Disease Severity, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Distribution Channel, Disease Severity, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Distribution Channel, Disease Severity, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel, Disease Severity, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kindred Biosciences (Elanco)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (diagnostics overlap)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health (now part of Elanco)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetIQ Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toray Industries (biologics involvement)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermcare-Vet Pty Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nextmune
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations